5 days later, we analyzed tumor infiltrates by flow cytometry and found that Afap1l2-edited OT-I T cells were more abundant in tumors than control OT-I T cells (18% vs. 10% of total CD8+ T cells in tumors) (Figures 6B and 6C), indicating that Afap1l2-edited T cells mounted a more robust response. The gene discussed is CD8A; the disease is neoplasm.